BRANFORD, Conn., June 1 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today the presentation and publication of interim clinical trial results with belinostat at the American Society of Clinical Oncology (ASCO) 2007 Annual Meeting, being held in Chicago, IL from June 2-5, and at the 2007 Pan Pacific Lymphoma Conference, being held in Maui, HI on June 11-15. CuraGen will host a conference call with management at 8:30 a.m. Eastern time on June 12, 2007, to discuss these results and to provide an update on the belinostat clinical development program.
Presentations at ASCO 2007 Annual Meeting
Title: A phase Ib/II study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors (Abstract #3501)
Session: Breaking the Silence of the Genome: HDAC Inhibitors Date / Time: Saturday, June 2, 2007, 3:30 - 3:45 p.m. Location: E450b
Title: A Phase I/II study of the safety and anti-cancer activity of IV-administered belinostat (PXD101) plus carboplatin (C) or paclitaxel (P), or both in patients with advanced solid tumors (Abstract #3574)
Session: Developmental Therapeutics: Molecular Therapeutics Date / Time: Sunday, June 3, 2007, 8:00 a.m. - 12:00 p.m. Location: S Hall A2 Poster board: J7
Abstracts published in the 2007 ASCO Annual Meeting Proceedings
Title: A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors (Abstract #14092)
Authors: W. K. Kelly, T. Yap, J. Lee, et al.
Title: A phase I/II study of belinostat (PXD101) in patients with unresectable hepatocellular carcinoma (Abstract #15081)
Authors: W. Yeo, R. Lim, B. Ma, et al.
Presentation at the 2007 Pan Pacific Lymphoma Conference
Title: A Phase II Study of Belinostat (PXD101) in Patients with Recurrent or Refractory Cutaneous or Peripheral T-Cell Lymphoma
Date: Monday, June 11 through Friday, June 15
Reprints of the poster presentations will be made available on CuraGen’s website at http://www.curagen.com or by emailing info@curagen.com
Conference Call Details and Dial-in Information Date: Tuesday, June 12, 2007 Time: 8:30 a.m. ET Dial-in: 877-272-5391 (domestic) 706-758-4315 (international) Passcode: 2474675
Webcast: Access to the live webcast is available at http://www.curagen.com
A replay of the conference call will be available starting at 11:30 a.m. Eastern time on Tuesday, June 12, 2007 through Sunday, August 12, 2007 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 2474675. An archive of the webcast will also be accessible at http://www.curagen.com
About Belinostat
Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including 5-FU, carboplatin, paclitaxel, cis-retinoic acid, azacitidine, doxorubicin and Velcade(R) (bortezomib) for Injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes and have been shown to: arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents.
Intravenous belinostat is currently being evaluated in multiple clinical trials as a potential treatment for multiple myeloma, T- and B-cell lymphomas, AML, mesothelioma, liver, soft tissue sarcoma, colorectal, ovarian cancers, either alone or in combination with anti-cancer therapies. An oral formulation of belinostat is also being evaluated in a Phase I clinical trial for patients with advanced solid tumors. In August 2004, CuraGen signed a Clinical Trials Agreement with the NCI under which the NCI is currently sponsoring multiple clinical trials investigating belinostat for the treatment of various cancers, both as a single-agent and in combination chemotherapy regimens. In May 2005, TopoTarget announced the signing of a Cooperative Research and Development Agreement (CRADA) with the NCI to conduct preclinical and nonclinical studies on belinostat in order to better understand its anti-tumor activity and to provide supporting information for clinical trials.
About CuraGen
CuraGen Corporation is a dedicated clinical-stage biopharmaceutical company developing diverse approaches, including novel protein, antibody, antibody-drug conjugate and small molecule therapeutics for the treatment of cancer and for cancer supportive care. CuraGen is currently conducting clinical trials to investigate the potential of velafermin, belinostat and CR011-vcMMAE. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com
Safe Harbor
Statements in this press release regarding management’s future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the presentation of interim clinical results with belinostat may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen’s drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen’s stage of development as a biopharmaceutical company, uncertainty of additional funding, CuraGen’s history of incurring losses and the uncertainty of achieving profitability, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen’s products, processes and technologies, CuraGen’s ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 filed with the Securities and Exchange Commission under the section “Risk Factors,” as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CRGN-P Contact: Glenn Schulman, Pharm.D. Director of Investor Relations gschulman@curagen.com (888) 436-6642
CuraGen Corporation
CONTACT: Glenn Schulman, Pharm.D., Director of Investor Relations ofCuraGen Corporation, +1-888-436-6642, gschulman@curagen.com
Web site: http://www.curagen.com/
